Author:
Ando Maki,Saka Hideo,Ando Yuichi,Minami Hironobu,Kuzuya Takafumi,Yamamoto Masashi,Watanabe Atsushi,Sakai Shuzo,Shimokata Kaoru,Hasegawa Yoshinori
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference25 articles.
1. Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K (1997) Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer 76:1067–1071
2. Belani CP, Hadeed V, Ramanathan R, Lembersky B, Agarwala S, Trump D, Jacobs S, Finley G, Hofacker J (1997) Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc Am Soc Clin Oncol 220a
3. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602–1613
4. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147
5. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5:533–537
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献